# Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

> **NCT02591199** · PHASE2 · TERMINATED · sponsor: **Urigen** · enrollment: 91 (actual)

## Conditions studied

- Interstitial Cystitis
- Bladder Pain Syndrome

## Interventions

- **DRUG:** URG101
- **DRUG:** Placebo
- **DRUG:** Lidocaine
- **DRUG:** Heparin

## Key facts

- **NCT ID:** NCT02591199
- **Lead sponsor:** Urigen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09
- **Primary completion:** 2018-05-14
- **Final completion:** 2018-06-18
- **Target enrollment:** 91 (ACTUAL)
- **Why stopped:** Prematurely terminated due to data inconsistent with the experimental plan and lack of funding
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02591199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02591199, "Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02591199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*